Biogen (BIIB) Has ~$20-$25 Downside on Negative Ruling - Mizuho

Mizuho Securities analyst Salim Syed said Biogen (NASDAQ: BIIB) hsa ~$20-$25 downside on the negative tecfidera ruling.

Syed notes BIIB can appeal, with the process taking 12-18 months.

The analyst reiterated a Neutral rating and $316.00 price target on BIIB.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $281.46 yesterday.

You May Also Be Interested In

• Wolfe Research Upgrades Biogen (BIIB) to Outperform
• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
• Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker